^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    carboplatin

    i
    Other names: CBDCA, JM-8, JM8, NSC-241240, NSC-241240, NSC 241240, NSC-241-240
    Company:
    Generic mfg.
    Drug class:
    Tubulin polymerization promoter
    Related drugs:
    1d
    Mindfulness-based stress reduction training and supplemented Jinshui Liujun decoction promote recovery in patients with non-small cell lung cancer. (PubMed, World J Psychiatry)
    MSRT + FJLD proved to be an effective treatment for patients with NSCLC.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    carboplatin • pemetrexed
    1d
    Cell death by apoptosis induced by Ocotea indecora (Schott) Mez essential oil in different cancer cell lines. (PubMed, Nat Prod Res)
    We performed cell viability using MTT (1000-31.25 μg/mL) using DMSO (negative) and carboplatin (positive) controls...Apoptosis is the main cell death pathway as indicated by the presence of active caspase 3/7 and morphological characteristics. In conclusion, the oil was effective against HEPG2 cells and could be considered for future cancer studies.
    Preclinical • Journal
    |
    CASP3 (Caspase 3) • CASP7 (Caspase 7)
    |
    carboplatin
    2d
    Debio 0123-101: Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=115, Recruiting, Debiopharm International SA | Trial completion date: Apr 2027 --> Nov 2027 | Trial primary completion date: Jun 2025 --> Nov 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    carboplatin • Debio 0123
    2d
    RELATIVITY-104: A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=468, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Sep 2025 --> Jan 2026
    Trial completion date • Metastases
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • relatlimab (BMS-986016)
    2d
    A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=42, Recruiting, Genmab | N=30 --> 42 | Trial primary completion date: Jul 2026 --> Mar 2026
    Enrollment change • Trial primary completion date
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • 5-fluorouracil • GEN1042
    2d
    GUIDANCE: Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P2, N=29, Enrolling by invitation, University of Cologne | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    Lynparza (olaparib) • cisplatin • carboplatin • Imfinzi (durvalumab) • etoposide IV
    2d
    SHR-1316-SCLC-LN-001: Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Small Cell Lung Cancer (clinicaltrials.gov)
    P=N/A, N=38, Recruiting, Yunpeng Liu | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1) • IL6 (Interleukin 6) • IL10 (Interleukin 10)
    |
    PD-L1 expression • CXCL8 expression • IL6 expression
    |
    cisplatin • carboplatin • AiTan (rivoceranib) • etoposide IV • Ariely (adebrelimab)
    2d
    Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). (clinicaltrials.gov)
    P3, N=308, Active, not recruiting, Incyte Corporation | Trial completion date: Oct 2024 --> Mar 2026 | Trial primary completion date: Oct 2024 --> Apr 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    CD4 (CD4 Molecule)
    |
    carboplatin • paclitaxel • Zynyz (retifanlimab-dlwr)
    2d
    A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) (clinicaltrials.gov)
    P3, N=1656, Not yet recruiting, Children's Oncology Group | Initiation date: Dec 2024 --> Mar 2025
    Trial initiation date
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • dactinomycin
    2d
    Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=10, Terminated, Rachel Sanborn | Trial completion date: Dec 2024 --> Feb 2024 | Active, not recruiting --> Terminated; Study enrollment was halted due to pandemic-related slow accrual
    Trial completion date • Trial termination
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • pemetrexed • etoposide IV
    2d
    Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, H. Lee Moffitt Cancer Center and Research Institute
    New P2 trial • Real-world evidence • Real-world
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed
    3d
    Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma. (PubMed, J Clin Oncol)
    This randomized phase III trial aimed to determine whether treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for four cycles (chemoradiotherapy [C-RT]) increased recurrence-free survival (RFS) and overall survival (OS) when compared with carboplatin and paclitaxel for six cycles (chemotherapy [CT]) in locally advanced endometrial cancer (UC). None of the factors analyzed predicted OS benefit from C-RT. Although C-RT reduced the rate of local recurrence compared with CT, it did not increase OS or RFS in stage III/IVA UC.
    P3 data • Journal • Metastases
    |
    NRG2 (Neuregulin 2)
    |
    cisplatin • carboplatin • paclitaxel
    3d
    SYNERGY: Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC (clinicaltrials.gov)
    P1/2, N=129, Active, not recruiting, Jules Bordet Institute | Trial completion date: Apr 2025 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD73 (5'-Nucleotidase Ecto)
    |
    HER-2 positive • HR positive • HER-2 negative • ER negative
    |
    carboplatin • Imfinzi (durvalumab) • paclitaxel • oleclumab (MEDI9447)
    3d
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=360, Not yet recruiting, Immatics US, Inc.
    New P3 trial • Metastases
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Opdualag (nivolumab/relatlimab-rmbw) • Amtagvi (lifileucel) • relatlimab (BMS-986016) • IMA203
    3d
    Fatal C-Reactive Protein-less Sepsis with Anti-IL-6 Autoantibody Production after Administration of Durvalumab. (PubMed, Intern Med)
    A 62-year-old woman with extensive-stage small-cell lung cancer received carboplatin-etoposide plus durvalumab chemotherapy. The serum tested positive for anti-interleukin-6 autoantibodies, which can cause CRP-less infections. Anti-interleukin-6 autoantibody production and subsequent sepsis without serum CRP elevation are possible irAEs.
    Journal
    |
    IL6 (Interleukin 6) • CRP (C-reactive protein)
    |
    carboplatin • Imfinzi (durvalumab) • etoposide IV
    4d
    Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine. (PubMed, Discov Oncol)
    Chemotherapy includes the use of doxorubicin or taxanes generally with platinum-based drugs viz. cisplatin or carboplatin that are administered alone or along with multitarget tyrosine kinase inhibitors viz. Lenvatinib, Sorafenib, Sunitinib, Vandetanib, Pyrazolo-pyrimidine compounds, etc., single target tyrosine kinase inhibitors like Dabrafenib plus Trametinib and Vemurafenib against BRAF, Gefitinib against EGFR, Everolimus against mTOR, vascular disruptors like Fosbretabulin, and immunotherapy with viz. Spartalizumab and Pembrolizumab, are anti-PD-1/PD-L1 molecules...Hence, our review presents a closer view of NDDS as a personalized treatment for TC. We have also discussed the primary challenges facing NDDS in meeting excellence in PM.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • Mekinist (trametinib) • cisplatin • Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • carboplatin • gefitinib • sorafenib • sunitinib • everolimus • Lenvima (lenvatinib) • doxorubicin hydrochloride • Caprelsa (vandetanib) • spartalizumab (PDR001) • Zybrestat (fosbretabulin)
    4d
    ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in MTNBC (clinicaltrials.gov)
    P1/2, N=78, Recruiting, Filipa Lynce, MD | Suspended --> Recruiting
    Enrollment open • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • azenosertib (ZN-c3)
    4d
    Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer (clinicaltrials.gov)
    P3, N=330, Active, not recruiting, Radiation Therapy Oncology Group | Trial completion date: Oct 2025 --> Oct 2028 | Trial primary completion date: Dec 2024 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • etoposide IV
    4d
    PERLA: Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=243, Completed, GlaxoSmithKline | Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Sep 2024
    Trial completion • Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF V600E • BRAF V600 • ALK mutation
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Jemperli (dostarlimab-gxly)
    4d
    NCI-2018-01581: Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Nov 2025 | Trial primary completion date: Dec 2024 --> Nov 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
    |
    PD-L1 expression • HER-2 negative • PD-L1 negative
    |
    carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • Imjudo (tremelimumab) • Trodelvy (sacituzumab govitecan-hziy) • Hiltonol (poly-ICLC)
    4d
    KANDOVA: A Study to Evaluate the Safety of KAND567, in Combination with Carboplatin Therapy, in Women with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=18, Active, not recruiting, Kancera AB | Recruiting --> Active, not recruiting | Phase classification: P2 --> P1/2 | N=30 --> 18 | Trial completion date: Jun 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
    Enrollment closed • Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD
    |
    carboplatin • KAND567
    4d
    ARTEMIDE-Lung03: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC (clinicaltrials.gov)
    P3, N=878, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • rilvegostomig (AZD2936)
    4d
    Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC (clinicaltrials.gov)
    P2, N=610, Recruiting, Henan Cancer Hospital | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • albumin-bound paclitaxel
    4d
    Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Case Comprehensive Cancer Center
    New P2 trial • Metastases
    |
    carboplatin • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    4d
    Fat Emulsion in Preventing Hypersensitivity Reactions in Patients With Cancer Receiving Carboplatin or Oxaliplatin (clinicaltrials.gov)
    P=N/A, N=19, Completed, Mayo Clinic | Active, not recruiting --> Completed
    Trial completion
    |
    carboplatin • oxaliplatin
    4d
    PROTECT: PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy (clinicaltrials.gov)
    P3, N=396, Recruiting, University of Aarhus | Trial completion date: May 2030 --> Dec 2032 | Trial primary completion date: May 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    carboplatin • paclitaxel
    4d
    MINIMA: Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca (clinicaltrials.gov)
    P2, N=32, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Nov 2024 --> Nov 2025
    Trial primary completion date • Metastases
    |
    carboplatin • paclitaxel • Libtayo (cemiplimab-rwlc)
    6d
    Transformation of a Testicular Teratoma to an Aggressive Primitive Neuroectodermal Tumor. (PubMed, Cureus)
    Treatment for the PNET included vincristine, doxorubicin, cyclophosphamide, and ifosfamide/etoposide mesna...The patient also underwent a tandem autologous stem cell transplant with carboplatin/etoposide conditioning and adjuvant etoposide and the subsequent PET/CT scan showed a response to the above treatment...The regimen for our patient yielded promising results. Our aim is to highlight a regimen that can be utilized for this rare aggressive neoplasm.
    Journal
    |
    AFP (Alpha-fetoprotein)
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine
    6d
    iMATRIX GLO: A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=65, Recruiting, Hoffmann-La Roche | Trial primary completion date: Oct 2027 --> Mar 2027
    Trial primary completion date • Combination therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    CD20 expression
    |
    carboplatin • Rituxan (rituximab) • Gazyva (obinutuzumab) • ifosfamide • etoposide IV • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)
    6d
    Tiragolumab and Atezolizumab in Patients with Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases (clinicaltrials.gov)
    P2, N=3, Active, not recruiting, Liza Villaruz, MD | Recruiting --> Active, not recruiting | N=35 --> 3 | Trial completion date: Apr 2029 --> Aug 2026 | Trial primary completion date: Sep 2027 --> Aug 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • carboplatin • pemetrexed • tiragolumab (RG6058)
    6d
    Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC (clinicaltrials.gov)
    P2, N=35, Recruiting, Beijing Chest Hospital, Capital Medical University | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Aug 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    carboplatin • albumin-bound paclitaxel • Ariely (adebrelimab)
    6d
    neovision: Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer (clinicaltrials.gov)
    P2, N=25, Recruiting, Guangdong Provincial People's Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    PD-L1 expression • HER-2 expression
    |
    carboplatin • Aidixi (disitamab vedotin) • Enweida (envafolimab)
    6d
    MOSAIC: Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance (clinicaltrials.gov)
    P=N/A, N=168, Completed, Peking University Cancer Hospital & Institute | Recruiting --> Completed
    Trial completion
    |
    cisplatin • carboplatin
    6d
    The Optimal Radioimmunotherapy Combinations for Advanced TNBC (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Sun Yat-sen University
    New P2 trial • Metastases
    |
    carboplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    6d
    Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer (clinicaltrials.gov)
    P2, N=105, Recruiting, Qilu Hospital of Shandong University
    New P2 trial • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • AiRuiYi (fluzoparib)
    9d
    A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLS) (MK-3475-01G/KEYMAKER U01) (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • patritumab deruxtecan (U3-1402)
    9d
    A Trial of GFH018 and Toripalimab in Combination with Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC (clinicaltrials.gov)
    P2, N=65, Active, not recruiting, Genfleet Therapeutics (Shanghai) Inc. | Trial completion date: Jan 2025 --> Jul 2025 | Trial primary completion date: Oct 2024 --> May 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    cisplatin • carboplatin • paclitaxel • Loqtorzi (toripalimab-tpzi) • pemetrexed • GFH018
    9d
    A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=504, Not yet recruiting, Shanghai Escugen Biotechnology Co., Ltd
    New P3 trial • Metastases
    |
    carboplatin • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • ESG401
    9d
    FUNDC1 predicts Poor Prognosis and promotes Progression and Chemoresistance in Endometrial Carcinoma. (PubMed, J Cancer)
    Knockdown of FUNDC1 using shRNA in HEC-1B and Ishikawa EC cells inhibited proliferation, migration and invasion, accompanied by enhanced chemotherapeutic susceptibility to carboplatin and paclitaxel. Accordingly, FUNDC1 could be a prospective prognostic biomarker and potential therapeutic target for EC.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • CD4 (CD4 Molecule)
    |
    HIF1A expression
    |
    carboplatin • paclitaxel
    9d
    Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Sichuan University
    New P1 trial
    |
    cisplatin • carboplatin • Loqtorzi (toripalimab-tpzi) • etoposide IV • tifcemalimab (TAB004)
    9d
    RATIONALE-314: Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=123, Recruiting, BeiGene | Trial completion date: Mar 2025 --> Feb 2026 | Trial primary completion date: Sep 2024 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • cytarabine • Tevimbra (tislelizumab-jsgr)
    10d
    Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas (clinicaltrials.gov)
    P1, N=321, Recruiting, Inhibrx Biosciences, Inc | N=240 --> 321 | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    cisplatin • carboplatin • 5-fluorouracil • temozolomide • pemetrexed • irinotecan • ozekibart (INBRX-109)